Lexicon Pharmaceuticals Reports Third Quarter Earnings Exceeding Estimates
Lexicon Pharmaceuticals (LXRX) reported third-quarter financial results that surpassed analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.03, beating estimates by $0.03, while revenue reached $11.3 million, exceeding projections by $7.16 million despite a 19.9% year-over-year decline. The company's liquidity position showed significant improvement during the period. As of September 30, 2024, Lexicon reported having $183.2 million in cash, investments, and restricted cash, up from $125.2 million in the prior year period.
Tickers: $LXRX
Topics: cash position earnings beat revenue report
Read the full article at Seeking Alpha
Part of the story NCR Voyix Reports Q3 Non-GAAP EPS of $0.32, Beating Estimates (4 articles)